BIIB033 (anti-LINGO-1 mAb) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Optic Neuritis
Conditions
Acute Optic Neuritis
Trial Timeline
Dec 1, 2012 → Oct 1, 2014
NCT ID
NCT01721161About BIIB033 (anti-LINGO-1 mAb) + Placebo
BIIB033 (anti-LINGO-1 mAb) + Placebo is a phase 2 stage product being developed by Biogen for Acute Optic Neuritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01721161. Target conditions include Acute Optic Neuritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01721161 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Optic Neuritis